105 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26810260	3	Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation.	Hanyang University
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School of Medicine At Mount Sinai
26396681	58	Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma.	Novartis Institutes For Biomedical Research
26526740	111	Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors.	Univ. Lille
26318056	25	Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.	Universit£
26342867	52	Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors.	Sichuan University
26318067	34	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.	Hanyang University
25965804	80	Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.	Eli Lilly
26071372	89	Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.	Astellas Pharma
25835317	63	Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.	Sichuan University
25086238	13	Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives containing diaryl urea moiety as potent antitumor agents.	Shenyang Pharmaceutical University
24878193	8	Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.	Hanyang University
25589930	62	Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.	Lexicon Pharmaceuticals
25440879	13	Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents.	Shenyang Pharmaceutical University
24773549	20	Discovery of 4-aryl-N-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 inhibitors. Part I: optimization of in vitro potencies and pharmacokinetic properties.	Development Center For Biotechnology
24675135	4	Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents.	Peking Union Medical College & Chinese Academy of Medical Sciences
24900832	29	Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.	Chugai Pharmaceutical
23550937	72	Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.	Emory University
23398453	4	Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.	Astrazeneca
23394126	170	Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).	Exelixis
23362959	72	Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.	Sichuan University
23398373	88	Design and optimization of selective protein kinase C¿ (PKC¿) inhibitors for the treatment of autoimmune diseases.	Vertex Pharmaceuticals
22521646	38	Novel triazolopyridylbenzamides as potent and selective p38a inhibitors.	RhôNe-Poulenc Rorer
22883026	34	Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives.	Takeda Pharmaceutical
23098265	46	Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.	University of Genoa
22808911	18	Conformation-specific effects of Raf kinase inhibitors.	Takeda California
22694093	16	Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.	National Institute of Biological Sciences
22548342	210	Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase¿ inhibitors.	Exelixis
22738630	76	Structure-based optimization of aminopyridines as PKC¿ inhibitors.	Vertex Pharmaceuticals
22721924	16	Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors.	Academy of Military Medical Sciences
22452518	22	Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.	Sichuan University
22335519	3	Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.	Genentech
22168626	32	Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.	Ambit Biosciences
21353571	26	Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.	Hanyang University
18183025	12060	A quantitative analysis of kinase inhibitor selectivity.	Ambit Biosciences
17850214	99	The selectivity of protein kinase inhibitors: a further update.	University of Dundee
18578517	93	Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.	Eberhard Karls University Tuebingen
18434146	28	Dual binding site inhibitors of B-RAF kinase.	Johnson & Johnson Pharmaceutical Research & Development
18359226	50	Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.	Bristol-Myers Squibb Research and Development
18077363	314	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.	University of Oxford
17983756	55	Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.	Osi Pharmaceuticals
18346893	43	Pharmacophore identification of Raf-1 kinase inhibitors.	China Pharmaceutical University
16876403	85	Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.	Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
15999997	85	Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.	Serono Pharmaceutical Research Institute
15013000	31	Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles.	Glaxosmithkline
11591521	39	Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach.	Bayer Research Center
10698440	12	The discovery of potent cRaf1 kinase inhibitors.	Glaxo Wellcome
22222036	9	Small molecule inhibitors of BRAF in clinical trials.	The Institute of Cancer Research
22014755	36	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.	Hanyang University
21999461	90	1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.	RhôNe-Poulenc Rorer
21958544	31	Indolin-2-one p38a inhibitors III: bioisosteric amide replacement.	RhôNe-Poulenc Rorer
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
21823617	58	9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors.	Chugai Pharmaceutical
21813275	40	Indolin-2-one p38a inhibitors II: Lead optimisation.	RhôNe-Poulenc Rorer
21576023	2	Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors.	Tsinghua University
21561771	39	Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors.	Chugai Pharmaceutical
21543226	26	Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors.	Novartis Institutes For Biomedical Research
20634068	2	Discovery and optimization of pyrazoline compounds as B-Raf inhibitors.	Millennium Pharmaceuticals
21391610	139	Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.	Vertex Pharmaceuticals
21376583	232	Discovery of triazine-benzimidazoles as selective inhibitors of mTOR.	Amgen
21353551	23	Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2.	Osi Pharmaceuticals
21420298	34	Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors.	Merck Serono
21341678	49	Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.	Millennium Pharmaceuticals
20961062	42	Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity.	Pfizer
20800479	33	Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.	Deciphera Pharmaceuticals
20797858	2	Synthesis of aminoquinazoline derivatives and their antiproliferative activities against melanoma cell line.	Institute of Science and Technology
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
19039322	50	Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.	Center For Molecular Medicine of The Austrian Academy of Sciences
17108987	2	New approaches to molecular cancer therapeutics.	The Institute of Cancer Research
16783341	34	Rational design of inhibitors that bind to inactive kinase conformations.	Novartis Research Foundation
20466542	6	1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors.	Institute of Science and Technology
20218619	44	Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.	Amgen
20166671	85	Selectively nonselective kinase inhibition: striking the right balance.	Schering-Plough
19864136	45	Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.	Wyeth Research
20148563	42	BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.	The Institute of Cancer Research
19888761	52	Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.	Hanmi Research Center
19356929	17	Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors.	Boehringer Ingelheim Pharmaceuticals
19338355	104	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.	University of Illinois At Chicago
18947905	51	Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.	China Pharmaceutical University
18818075	25	The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.	Glaxosmithkline
18691885	60	Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.	Ariad Pharmaceuticals
18602262	56	Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes.	Glaxosmithkline
17848581	13	Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood.	Wyeth Research
17560108	5	New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site.	Boehringer Ingelheim Pharmaceuticals
16931012	61	Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors.	Targegen
16890436	3	Aza-stilbenes as potent and selective c-RAF inhibitors.	Glaxosmithkline
16765046	63	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.	Chiron
15943486	8	Rapid computational identification of the targets of protein kinase inhibitors.	University of Iowa
15454231	32	A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis.	Astrazeneca
15177482	90	Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.	Novartis Institutes For Biomedical Research
14741289	43	Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent.	Bayer Research Center
12086485	10	Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.	Boehringer Ingelheim Pharmaceuticals
11934592	24	Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor.	Merck Research Laboratories
11597418	47	Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity.	Glaxosmithkline
11378364	34	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.	Research Biomet. Glaxo Wellcome Medicines Research Centre
10377223	57	Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.	Merck Research Laboratories
9873604	72	Pyrroles and other heterocycles as inhibitors of p38 kinase.	Merck Research Laboratory
16339913	6	Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter.	University of Tours
2885412	25	Alpha-1 adrenergic receptor binding in aortas from rat and dog: comparison of [3H]prazosin and beta-iodo-[125I]-4-hydroxyphenyl-ethyl-aminomethyl-tetralone.	Unwersity of Misscuri